Publications by authors named "Michael Devitt"

Claim this Profile
M
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).
Irene Tsung, David C Smith, Elisabeth I Heath, Frank Cackowski, Michael E Devitt

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.
Karen A Autio, Christos E Kyriakopoulos, Paul Palyca, Han Xiao, Hamid Emamekhoo, Michael Devitt

Invest New Drugs· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review.
Mark Willy L Mondia, Prem P Batchala, Robert Dreicer, Michael E Devitt, Matthew R McCord

Prostate· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When You Get to the Fork in the Road, Take It: The Challenges in Managing Patients With Advanced Prostate Cancer.
Paul Viscuse, William P Skelton, Michael M Devitt, Robert Dreicer

JCO Oncol Pract· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRI-Guided Adaptive Radiation Therapy for Oligometastatic Prostate Cancer Involving the Adrenal Gland: A Case Report and Literature Review.
Fabian J Bolte, Christopher K Luminais, Matthew Mistro, Michael E Devitt

Case Rep Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Renin-Angiotensin System Inhibitors on Response to PD1/L1 Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Kathryn Fortune, Soham Ali, Jack Masur, Paul Viscuse, Michael Devitt

Clin Genitourin Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The New-Meaning Objection: A Reply to Nicolò D'Agruma.
Michael Devitt, Nicolas Porot

Cogn Sci· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of DPP4 Inhibition on Survival in Patients With Metastatic Renal Cell Carcinoma and Type 2 Diabetes Mellitus.
Soham Ali, Kathryn Fortune, Jack Masur, Paul Vincent Viscuse, Michael Edward Devitt

Clin Genitourin Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.
Patricia J Keller, Elizabeth J Adams, Rentian Wu, Alexandre Côté, Shilpi Arora, Michael Devitt

Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
Paul Viscuse, Michael Devitt, Robert Dreicer

J Nucl Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Unusual Renal Mass: Thinking Beyond Renal Cell Carcinoma.
Sumit Isharwal, Emily Ayers, Rachita Khot, Srishti Gupta, Michael Devitt

Urology· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenosquamous carcinoma of the prostate with low PSMA expression.
Sumit Isharwal, Michael Devitt, Srishti Gupta, Ayman Mithqal, Yasmeen K Tandon

Int Urol Nephrol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
Sarmad Sadeghi, David Quinn, Tanya Dorff, Sumanta Pal, Susan Groshen, Michael Devitt

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Rafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas N Diamantopoulos, Scott Dawsey, Michael E Devitt

Clin Genitourin Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
Dimitrios Makrakis, Rafee Talukder, Leonidas N Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Michael E Devitt

BJU Int· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Dimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N Diamantopoulos, Scott Dawsey, Michael E Devitt

Clin Genitourin Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
Rafee Talukder, Dimitrios Makrakis, Leonidas N Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Michael E Devitt

Clin Genitourin Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
Stepan M Esagian, Ali Raza Khaki, Leonidas N Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Michael E Devitt

BJU Int· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
Ali Raza Khaki, Ang Li, Leonidas N Diamantopoulos, Natalie J Miller, Lucia Carril-Ajuria, Michael Devitt

Eur Urol Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing the Reference of Biological Kind Terms.
Michael Devitt, Brian C Porter

Cogn Sci· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
Natalie J Miller, Ali Raza Khaki, Leonidas N Diamantopoulos, Mehmet A Bilen, Victor Santos, Michael Devitt

J Urol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Ali Raza Khaki, Ang Li, Leonidas N Diamantopoulos, Mehmet A Bilen, Victor Santos, Michael Devitt

Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving Role of Genomics in Genitourinary Neoplasms.
Michael E Devitt, Robert Dreicer

Acta Med Acad· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Major Bleeding with Ibrutinib.
Joseph Mock, Paul R Kunk, Surabhi Palkimas, Jeremy M Sen, Michael Devitt

Clin Lymphoma Myeloma Leuk· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Historical biological essentialism.
Michael Devitt

Stud Hist Philos Biol Biomed Sci· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis